Key Takeaways
- Tech stocks saw a rebound, with the NASDAQ up over 2%, driven by optimism for a government shutdown resolution.
- Coreweave reported strong Q3 results with a $55 billion backlog, yet its stock experienced a drop.
- The AI infrastructure build-out faces significant challenges, particularly concerning power capacity and supply chain delays.
- Key pharmaceutical players, Pfizer and Eli Lilly, made headlines with acquisitions and market valuation milestones.
- Concerns about market concentration and the disconnect between productivity gains and labor market struggles persist.
Deep Dive
- Coreweave reported third-quarter results that surpassed revenue and operating margin estimates.
- The company's contracted backlog significantly increased to $55 billion from $30 billion in Q2, including deals with Meta ($14 billion) and OpenAI ($6.5 billion).
- Despite strong backlog growth, Coreweave's stock saw a slight drop, with analysts suggesting the backlog could have been higher.
- Adjusted EBITDA margins of 61.5% were identified as a potential factor in the stock's stagnant movement.
- Discussion centered on hyperscalers' substantial capital expenditures and the viability of smaller companies like Coreweave versus giants such as Microsoft.
- Concerns were raised regarding potential GPU oversupply and margin pressures within the sector.
- It was argued that cash-flow generative hyperscalers are better positioned to handle these investments, given their market capitalization.
- A Senate vote on a government reopening deal was anticipated within hours, expected to extend operations for several months.
- Attention shifted to a potential December vote on healthcare premium tax credits.
- A Republican senator criticized the focus on these tax credits, advocating for broader Affordable Care Act reform, including health savings plans.
- Concerns were expressed over market concentration, with only 15-20 stocks driving overall performance.
- Revised job creation figures indicated growth is primarily productivity-driven rather than a strong labor market.
- A disparity exists between productivity gains in certain market segments and labor struggles in others, impacting consumer spending.
- The concentration of stock ownership among a small percentage of the population was noted as a potential policy issue.
- Pfizer secured Metzera for up to $10 billion, ending a bidding war with Novo Nordisk; Metzera's shares fell 15% as it has no treatments on the market.
- Eli Lilly's stock reached an all-time high, nearing a $1 trillion market cap, following an upgrade from Leer Inc.
- The upgrade for Eli Lilly cited Medicare and Medicaid access driving obesity treatment adoption.
- Major League Baseball is implementing new rules with sports book partners to limit prop and parlay bets on individual pitches, capping bets at $200.
- This move aims to curb integrity risks associated with micro-betting, following a scandal involving pitchers Emmanuel Clase and Luis Ortiz.
- Traders believe the market for companies like DraftKings remains strong despite regulations, with concerns focused on competitive balance, margin profiles, and stock valuation.
- Coreweave's stock fell approximately 6% in after-hours trading due to delays from a third-party data center provider impacting power shell deliveries.
- This delay pushed Q4 revenue recognition into Q1, though the contract value remains intact.
- The company's Q3 capital spending was lower at $1.9 billion due to these supply chain challenges with power shell infrastructure, not a lack of power itself.
- Paramount Global's shares rose after hours despite revenue misses, driven by increased targets for cost-saving measures and planned subscription price hikes for Paramount Plus.
- CEO David Ellison stated the company does not have 'must-haves' and can build organically but has the balance sheet for opportunistic moves.
- Analysts discussed the potential for a 'rebundling' of media properties, citing Paramount's valuable assets and the influx of capital into the sector.